DUALITY BIOLOGICS
“To Translate Novel Modality into Reality”. Duality Biologics was founded in January 2020 by Dr. John Zhu, a well-respected investor in the healthcare industry. Duality Bio is committed to developing novel modality drugs to fulfill the unmet medical needs for patients worldwide. Focusing on the oncology and autoimmune diseases, the company has built a novel internal pipeline including nearly 10 Best-in-Class and First-in-Class bispecific antibody and Antibody-Drug Conjugate (ADC) drugs, of which several drug candidates are in the IND stage. The company has successfully built the next-generation ADC platform with global intellectual property rights. The value of this platform has been validated by a number of drug candidates under development.
DUALITY BIOLOGICS
Social Links:
Industry:
Biopharma Biotechnology Health Care Medical
Founded:
2020-01-01
Address:
Shanghai, Shanghai, China
Country:
China
Website Url:
http://www.dualitybiologics.com
Total Employee:
11+
Status:
Closed
Email Addresses:
[email protected]
Total Funding:
90 M USD
Similar Organizations
Dare Bioscience
Daré Bioscience is a healthcare company committed to the development and commercialization of innovative products.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
OnQuality Pharmaceuticals
OnQuality Pharmaceuticals involves in development and commercialization of innovative drugs and drug delivery systems.
TOT BIOPHARM
TOT BIOPHARM is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative oncology drugs.
Current Employees Featured
Founder
Investors List
Oriza Holdings
Oriza Holdings investment in Series B - Duality Biologics
Lilly Asia Ventures
Lilly Asia Ventures investment in Series B - Duality Biologics
Huagai Capital
Huagai Capital investment in Series B - Duality Biologics
WuXi Biologics
WuXi Biologics investment in Series B - Duality Biologics
Green Pine Capital Partners
Green Pine Capital Partners investment in Series B - Duality Biologics
NRL Capital
NRL Capital investment in Series B - Duality Biologics
Official Site Inspections
http://www.dualitybiologics.com
- Host name: 223.166.75.128
- IP address: 223.166.75.128
- Location: Shanghai China
- Latitude: 31.0449
- Longitude: 121.4012
- Timezone: Asia/Shanghai
More informations about "Duality Biologics"
To Become A Global ADC Powerhouse-DualityBio
Dec 31, 2024 For more information, please visit www.dualitybiologics.com. Learn More. 2025-01-13. Voluntary Annuoncement Cooperation Between 3SBio Inc. And Duality Biol Ogics In …See details»
抗体偶联药物ADC领域的全球领跑者-映恩生物
映恩生物是一家临床阶段的创新生物药企，专注于为癌症和自身免疫性疾病患者研发新一代抗体偶联药物（adc）。公司已成功构建了多个具有全球知识产权的新一代adc技术平台。基于对疾病生物学机制的深入研究和探索，映恩生物拥有丰 …See details»
Duality Biologics - Crunchbase Company Profile
Organization. Duality Biologics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Duality …See details»
Global Cooperations - en.dualitybiologics.com
DB-1303/BNT323(HER2) DB-1311/BNT324(B7-H3) DB-1305/BNT325(TROP2) BioNTech is a global leader in next-generation immunotherapy, pioneering innovative treatments for cancer, …See details»
Duality Biologics-Duality Biologics
Duality Bio is a biotech company based in China. Our mission is to become the development and commercialization engine house for next generation biologics, and to provide innovative …See details»
Investor Relations - en.dualitybiologics.com
[email protected]. Address. 11th Floor, Building A, Jiangong Datang International Plaza, 868 Sakura Road, Pudong New Area, Shanghai Scan the code to follow DualityBio official …See details»
Duality Biologics Overview | SignalHire Company Profile
Organization Website. dualitybiologics.com . Duality Biologics industries. Biotech Headquarters Location. Shanghai, CN. Duality Biologics Employees Size. 100-200 employees. Specialties. …See details»
Duality Biologics (Suzhou) Co. Ltd. (DualityBio) - Life-Sciences …
Apr 3, 2023 BIO (US) (Biotechnology Innovation Organization, formerly Biotechnology Industry Organization) ASMS (American Society for Mass Spectrometry) Israel Life Science Industry …See details»
关于我们 - dualitybiologics.com
Db-1303获得fda fast track认定. db-1303 ph2临床试验入组第一个病人. db-1310获得fda ind批准. db-1311获得fda ind批准. db-1310获得中国 ind批准See details»
DualityBio 2025 Company Profile: Valuation, Funding
Information on valuation, funding, cap tables, investors, and executives for DualityBio. Use the PitchBook Platform to explore the full profile.See details»
Duality Biologics - Products, Competitors, Financials, Employees ...
Dualitybiologics.com. Overview & Products; Financials; Founded Year 2020. Stage Series B | Alive. Total Raised $120M. Last Raised $90M | 4 yrs ago. About Duality Biologics. Duality …See details»
Duality Biologics - Overview, News & Similar companies - ZoomInfo
Duality Biologics contact info: Phone number: +86 2126018730 Website: www.dualitybiologics.com What does Duality Biologics do? Duality Bio is a global clinical stage …See details»
Science and Technology - en.dualitybiologics.com
Meanwhile, we have established close cooperation with outstanding domestic partners, leveraging their professional contract sales organization (CSO) capabilities to fully advance the launch …See details»
DualityBio (Duality Biologic) - VentureRadar
"DualityBio is committed to developing novel modality drugs for oncology and autoimmune diseases. The company has built a novel internal pipeline including nearly 10 Best-in-Class …See details»
Duality Biologics | CipherBio
Explore Duality Biologics's investment information, scientific platforms, therapeutic approaches, indications and more here!See details»
全球合作 - dualitybiologics.com
如果您有兴趣与我们共同探索合作机会，请将您的请求发送至全球合作联系邮箱：[email protected] 融入全球制药产业链，成为全球ADC创新引擎 中国See details»
Duality Biologics Completed $90 Million Series B Financing
[email protected] About Lilly Asia Ventures Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm founded in 2008, with offices in Shanghai , Hong Kong , and …See details»
Duality Biologics Announces License Agreement of its Next
January 5th, 2023 Duality to grant license of DITAC (Duality Immune Toxin Antibody Conjugates) platform to Adcendo for its lead uPARAP ADC program Duality to receive upfront payment, …See details»
Duality Biologics and BioNTech Presented Positive Interim Data for ...
CONTACT: DualityBio Enquiries, Media/Investor Relations: [email protected]. Drug supply project. 2025-04-07. Duality Bio Appoints Hua Mu as Global Chief Medical Officer. 2025-01 …See details»
Duality Biologics Completed $90 Million Series B Financing - PR …
May 20, 2021 PRINCETON, N.J. and SHANGHAI and SUZHOU, China, May 19, 2021 /PRNewswire/ -- Duality Biologics (DualityBio or Company), an innovative biotech company, …See details»